ARTHUR-D.-LITTLE
6.3.2023 13:02:36 CET | Business Wire | Press release
Arthur D. Little (ADL) has published the fourth edition of its Autonomous Mobility Journal, which looks at the latest developments in autonomous vehicles (AVs) and the market for autonomous mobility going forward.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005447/en/
Arthur D. Little: Autonomous Mobility Journal, Fourth Edition (Graphic: Business Wire)
As well as highlighting current industry dynamics, the journal also includes:
- A special focus on robotaxis around the world
- An overview of the AV market in Hong Kong
- An interview with Prof. Omaimah Bamasag, Deputy of Transport Enablement at the Transport General Authority of the Kingdom of Saudi Arabia
While the AV market remains in its infancy and, like other industries, has suffered setbacks due to the Covid-19 pandemic and semiconductor shortages, companies are still working hard to advance AV technologies to the point of mainstream acceptance and deployment. The buoyancy of the global electric vehicle (EV) market also provides a technology pathway for autonomous mobility features to be more readily adopted in the coming years.
An interesting aspect of the autonomous mobility landscape is the high number of start-ups in this space that have gone public through special-purpose acquisition companies (SPACs) rather than more conventional IPOs. Many of these companies have shown fragility and lack of resilience in a difficult market context – however, it is hoped that increased focus on EV innovation by major OEMs will create additional traction in the AV market, and boost the prospects of AV start-ups.
ADL believes that the outlook for robotaxis is more positive, with “city robotaxis” which can operate in any mapped area of a city, even in extreme weather conditions, likely by 2027. “Anywhere robotaxis”, which can operate on unmapped or unmade roads, could also be a reality by 2030.
ADL’s analysis of the AV market in Hong Kong reveals how it has positioned itself as a leader in the autonomous mobility ecosystem through the successful coordination of key elements, including strategy, regulations, stakeholder integration, infrastructure and technology. Finally, Prof. OmaimahBamasag outlines Saudi Arabia’s ambitious goals for AV transport, including major autonomy-based initiatives such as the Neom and Red Sea projects in the Kingdom’s economic zone.
Joseph Salem, Partner in ADL’s Travel & Transportation practice, comments: “While the development of autonomous mobility solutions globally remains experiential, industry players are clearly on the lookout for technological and business model innovation to unlock value-creating use cases. In this journal, we provide a realistic overview of recent developments and industry dynamics, including the key considerations and challenges that the AV market currently faces. We hope it provides food for thought and look forward to feedback from our readers.”
The journal is available for download here: https://tinyurl.com/24cr7dxj
For further information, please visit www.adlittle.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005447/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
